Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Eur J Intern Med 130:8697 Schimmel K, Ichimura K, Reddy S, Haddad F, Spiekerkoetter E (2022) Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target
New products, lab updates, and research resources delivered direct.
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
Zhang, J
US$ 26.26
US$ 22.69
US$ 22.82
US$ 26.57
US$ 27.93
US$ 26.39
US$ 24.43
US$ 22.39
